\documentclass[10pt,aspectratio=169]{beamer}
\usetheme{metropolis}
\usepackage{appendixnumberbeamer}
\usepackage{booktabs}
\usepackage{graphicx}
\usepackage{tikz}
\usepackage{amsmath}
\usepackage{xcolor}

% Define NHS colors
\definecolor{nhsblue}{RGB}{0,94,184}
\definecolor{nhsdarkblue}{RGB}{0,48,135}
\definecolor{nhsgreen}{RGB}{0,177,64}
\definecolor{nhsred}{RGB}{218,41,28}

% Set theme colors
\setbeamercolor{frametitle}{bg=nhsblue,fg=white}
\setbeamercolor{progress bar}{fg=nhsgreen}
\setbeamercolor{title separator}{fg=nhsblue}
\setbeamercolor{alerted text}{fg=nhsred}

\metroset{progressbar=frametitle,sectionpage=progressbar,numbering=fraction}

\title{Agent-Based Simulation for Neovascular AMD Treatment Planning}
\subtitle{Optimizing Anti-VEGF Therapy Protocols in the NHS}
\author{Luke Herbert\\Consultant Ophthalmologist}
\institute{Surrey and Sussex Healthcare NHS Trust}
\date{24th June 2025}

\begin{document}

\maketitle

% Acknowledgments in title frame note
\begin{frame}{Acknowledgments}
\begin{itemize}
    \item Health Service Modelling Associates (HSMA) team
    \item Finance Director and IT Director
    \item NHS England Pharmacy \& Clinical Support Team
\end{itemize}
\end{frame}

\section{Understanding Neovascular AMD}

\begin{frame}{What is Neovascular AMD (NAMD)?}
\begin{columns}[T]
\column{0.5\textwidth}
\begin{itemize}
    \item Leading cause of central vision loss
    \item Cannot read or recognize faces
    \item Leads to legal blindness if untreated
    \item Affects quality of life severely
\end{itemize}

\column{0.5\textwidth}
\begin{figure}
    \centering
    \includegraphics[width=0.8\textwidth]{logMAR_chart_explainer.png}
    \vspace{0.3cm}
    \includegraphics[width=0.8\textwidth]{namd_angiography.png}
\end{figure}
\end{columns}
\end{frame}

\begin{frame}{The Biology Behind NAMD}
\begin{columns}[T]
\column{0.6\textwidth}
\textbf{Disease Process:}
\begin{itemize}
    \item Aging eye environment
    \item Increased VEGF (Vascular Endothelial Growth Factor)
    \item Abnormal blood vessel growth
    \item Leakage, fibrosis, and bleeding
\end{itemize}

\column{0.4\textwidth}
\begin{exampleblock}{VEGF?}

  VEGF is like fertiliser for blood vessels. Anti-VEGF is something that removes the fertiliser.

  As VEGF keeps being made we have to keep removing it.
  \end{exampleblock}
\end{columns}
\end{frame}

\begin{frame}{Revolutionary Treatment: Anti-VEGF Therapy}
\begin{columns}[T]
\column{0.6\textwidth}
\textbf{How it works:}
\begin{itemize}
    \item Antibodies or similar molecules bind to VEGF
    \item Remove growth factor from eye
    \item Stop abnormal vessel growth
\end{itemize}

\vspace{0.5cm}
\alert{\textbf{The Challenge:}}
\begin{itemize}
    \item Molecules cleared over time
    \item Requires repeated injections
    \item Optimal frequency unknown
\end{itemize}

\column{0.4\textwidth}
\begin{figure}
    \centering
    \begin{tikzpicture}[scale=0.7]
        % VEGF binding diagram
        \node[circle,draw,nhsred,thick,minimum size=1cm] (vegf) at (0,2) {VEGF};
        \node[draw,nhsblue,thick,minimum width=1.5cm] (ab) at (0,0) {Anti-vegf};
        \draw[->,thick] (vegf) -- (ab);
        \node[right] at (1.5,1) {Binding};
    \end{tikzpicture}
\end{figure}
\end{columns}
\end{frame}

\begin{frame}{Real-World Treatment Challenges}
\begin{alertblock}{Why Patients Stop Treatment}
\begin{itemize}
    \item \textbf{Mortality}: Elderly population (average age 80+)
    \item \textbf{Frailty}: Too unwell to attend monthly appointments
    \item \textbf{Treatment failure}: Vision deteriorates despite therapy
    \item \textbf{NHS capacity}: Limited appointment availability
\end{itemize}
\end{alertblock}

\begin{block}{Discontinuation Rates}
\begin{itemize}
    \item Year 1: 10-15\% stop treatment
    \item Year 2: Additional 10-15\%
    \item By Year 5: Only 50-60\% still on treatment
\end{itemize}
\end{block}

\centering
\textbf{Critical Question: How do we optimise treatment for those who remain?}
\end{frame}

\section{The Cost Challenge}

\begin{frame}{NHS Annual Treatment Costs}
\begin{table}
\centering
\begin{tabular}{lrr}
\toprule
Treatment Area & Annual NHS Spend & Annual Patient Numbers \\
\midrule
\alert{Wet AMD (Anti-VEGF)} & \alert{£600-800 million} & 40,000 new, ~200,000 continuing \\
Cataract Surgery & £320-480 million & 400,000 \\
Hip Replacement & £500-700 million & 100,000 \\
\bottomrule
\end{tabular}
\end{table}

\vspace{0.3cm}
\begin{alertblock}{Cost per QALY}
\begin{itemize}
    \item Cataract surgery: £1,964 per QALY (exceptional value)
    \item Hip replacement: £2,128 per QALY (strong value)
    \item \alert{Wet AMD: £58,047 per QALY (3x NICE threshold)}
\end{itemize}
\end{alertblock}

\begin{block}{Current Anti-VEGF Drug Costs (2024 list prices)}
\begin{itemize}
    \item Aflibercept (Eylea): £816 a dose, generic soon maybe £400
    \item Patients need 7-10 injections year 1, then 4-6/year ongoing
\end{itemize}
\end{block}

\centering
\textbf{Challenge: £1.2-1.5 billion projected cost by 2035}
\end{frame}

\end{document}